Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. is a U.S.-based radiopharmaceutical company focused on developing targeted alpha therapies for cancer. The company combines clinical-stage drug development with owned and operated manufacturing facilities in the United States to support production, testing, and future commercialization of its program candidates.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueAlpha-emitting oncology drug candidates in preclinical and clinical development.
Research support tied to work performed for the National Institutes of Health.
Customers
Perspective Therapeutics primarily serves cancer patients indirectly through hospitals, oncology centers, and clinical trial sites that administer its investigational therapies. Its current revenue base is tied to NIH-supported research work, while future commercial customers would include nuclear medicine centers and cancer treatment networks that use radiopharmaceutical products.
Hospitals and research centers that enroll patients and administer investigational radiopharmaceuticals in Phase 1/2 studies.
The National Institutes of Health funds or supports research work that generates grant revenue.
Cancer centers and nuclear medicine practices that could buy approved therapies for patient treatment.
Strategy
Perspective Therapeutics is building a vertically integrated radiopharmaceutical platform by advancing clinical assets, expanding manufacturing capacity, and preparing for future commercialization. Its strategy also includes adding personnel, protecting intellectual property, and pursuing additional program candidates through acquisition or in-license.
Clinical success is the main path to future product revenue and value creation.
Radiopharmaceuticals require specialized production, handling, and distribution infrastructure.
Approved therapies will require manufacturing, distribution, and market access capabilities.
Geography
The company is headquartered in the United States and operates manufacturing and development activities across several U.S. metropolitan areas. Its facility footprint includes Somerset, New Jersey, and acquired or planned sites in Houston, Chicago, and Los Angeles, supporting future clinical and commercial supply in major U.S. cancer-treatment markets.
Risks
The company faces the typical risks of clinical-stage biotechnology, including trial failure, regulatory delays, and the need for substantial external funding before product sales begin. Its specialized manufacturing strategy also creates execution risk around facility buildout, equipment validation, and reliable supply of radiopharmaceutical products.
The company’s value depends on proving safety and efficacy in human trials.
Even successful trials may not translate into marketing approval or timely labeling decisions.
Exposure: All current and future program candidates
The business is pre-commercial and may need repeated capital raises to fund R&D and capex.
Exposure: ATM equity program and future financing needs
Radiopharmaceutical production requires validated facilities, equipment, and tight logistics.
Accounting
Judgemental itemsRevenue currently comes from NIH-related work, so timing and scope of reimbursable work affect reported sales.
Impact: Separates research support from future commercial product revenue
Clinical trials, drug product costs, and delivery costs are expensed as incurred, affecting operating loss timing.
Impact: Quarterly R&D volatility and comparability
Facility acquisitions and manufacturing equipment installation require capitalization, depreciation, and lease judgments.
Impact: Affects balance sheet asset values and future expense recognition
Cash and investment balances are important to funding runway and may include valuation-sensitive instruments.
Impact: Can affect other income and liquidity presentation
Similar listed companies
Publicly listed companies with a comparable business focus.
Context Therapeutics Inc.
CNTX · Pharmaceutical Preparations
Marker Therapeutics, Inc.
MRKR · Pharmaceutical Preparations
Intensity Therapeutics, Inc
INTS · Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
PMV Pharmaceuticals, Inc.
PMVP · Pharmaceutical Preparations
PMV Pharmaceuticals is a U.S.-based clinical-stage biotechnology company focused on developing small-molecule cancer therapies, with an emphasis on genomically defined tumors.
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Last updated: 24/09/2026